Cologne, March 17, 2015 – New Oncology today announced the completion of a financing round to prepare the market launch of NEOliquid, a non-invasive blood test that identifies therapeutically actionable genome alterations in the circulating free tumour DNA (ctDNA) of cancer patients. NEOliquid allows detection not only of mutations, but also of therapeutically relevant gene fusions (e.g. affecting ALK, ROS or RET kinases) with the highest sensitivity and confidence. Existing shareholders as well as additional investors participated in this financing round. Financial details were not disclosed.
“We are excited about the prospect of identifying therapeutically relevant genome alterations without the need to perform painful biopsies. This financing round is a critical step towards this important goal." commented Prof. Roman Thomas, founder of New Oncology.
About New Oncology
New Oncology’s proprietary diagnostic platform ‘NEO’ empowers physicians to make optimal decisions about the most suitable targeted therapy for their patients, including participation in suitable clinical trials. Our pan-cancer diagnostic test NEOplus reliably detects actionable genome alterations from one single patient sample with short turn-around times. In contrast to conventional testing, NEOplus identifies all types of therapeutically relevant alterations, i.e. mutations, amplifications, insertions/deletions, as well as known and novel translocations, from the smallest quantities of routine tumour specimens. New Oncology works with a tumour board comprising renowned cancer experts, facilitating translation of the latest targeted therapy findings into optimized patient care.
NEO New Oncology AG